Investigating the Therapeutic Potential of MSC-EVs in Neonatal HIE.

Perinatal hypoxic-ischemic encephalopathy (HIE) is a severe brain injury in newborns and could cause long-term neurological developmental disorders. Mesenchymal stem cell-derived extracellular vesicles (MSC-EVs) are increasingly regarded as an effective cell-free therapeutic approach due to their low immunogenicity, natural ability to cross the blood-brain barrier, and engineerable properties. This review indicates that MSC-EVs can achieve better therapeutic effects by specifically regulating the immune response and promoting repair at different stages of neuroinflammation. It systematically summarizes engineering optimization strategies to enhance the therapeutic effect of MSC-EVs, including reprogramming EV components via hypoxia or drug pretreatment and improving EV biological activity and tissue bioavailability through 3D culture combined with biomaterial delivery systems. Additionally, it analyzes the efficacy, advantages, and limitations of different administration routes for the treatment of cerebral ischemia-hypoxia diseases. Finally, it discusses the limitations of MSC-EVs in the treatment of HIE and future research directions, providing a comprehensive theoretical basis for the clinical translation of MSC-EVs as a targeted treatment for neonatal HIE.

Authors

Institutions

Publication Details

Journal
PubMed
Published
2026-11-17
DOI
https://doi.org/10.2174/011574888x498122261113115058
Primary Topic
Extracellular vesicles in disease
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Investigating the Therapeutic Potential of MSC-EVs in Neonatal HIE.

Mengsi Lin, Maorong Jiang, Dengbing Yao, Yi Yao et al.
PubMed
Extracellular vesicles in disease
article

Investigating the Therapeutic Potential of MSC-EVs in Neonatal HIE.

Mengsi Lin, Maorong Jiang, Dengbing Yao, Yi Yao, Min Cai, Xi Gu, Hui Xu, Yiming Xia
article en

Abstract

Perinatal hypoxic-ischemic encephalopathy (HIE) is a severe brain injury in newborns and could cause long-term neurological developmental disorders. Mesenchymal stem cell-derived extracellular vesicles (MSC-EVs) are increasingly regarded as an effective cell-free therapeutic approach due to their low immunogenicity, natural ability to cross the blood-brain barrier, and engineerable properties. This review indicates that MSC-EVs can achieve better therapeutic effects by specifically regulating the immune response and promoting repair at different stages of neuroinflammation. It systematically summarizes engineering optimization strategies to enhance the therapeutic effect of MSC-EVs, including reprogramming EV components via hypoxia or drug pretreatment and improving EV biological activity and tissue bioavailability through 3D culture combined with biomaterial delivery systems. Additionally, it analyzes the efficacy, advantages, and limitations of different administration routes for the treatment of cerebral ischemia-hypoxia diseases. Finally, it discusses the limitations of MSC-EVs in the treatment of HIE and future research directions, providing a comprehensive theoretical basis for the clinical translation of MSC-EVs as a targeted treatment for neonatal HIE.

PubMed
Nantong University (CN), Nantong Maternity and Child Health Hospital (CN)
Extracellular vesicles in disease
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon